

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY
CONVEYING PARTY DATA	
Name	Execution Date
JPMorgan Chase Bank, N.A.	03/04/2011
RECEIVING PARTY DATA	
Name:	General Nutrition Investment Company
Street Address:	1002 South 63rd Avenue at Buckeye
City:	Phoenix
State/Country:	ARIZONA
Postal Code:	85043
PROPERTY NUMBERS Total: 36	
Property Type	Number
Patent Number:	6546702
Application Number:	10535330
Application Number:	09662123
Application Number:	09613573
Application Number:	09726308
Application Number:	09581475
Application Number:	09880937
Application Number:	10480487
Application Number:	09812839
Application Number:	10608095
Application Number:	09956463
Application Number:	10384750
Application Number:	10535258
Application Number:	10323826
Application Number:	10325711

501457506

PATENT
REEL: 025905 FRAME: 0054

CH \$1440.00 6546702

Application Number:	09639469
Application Number:	10284158
Application Number:	10239429
Application Number:	09734389
Application Number:	10612242
Application Number:	10015582
Application Number:	10496411
Application Number:	08691023
Application Number:	09769245
Application Number:	10279968
Patent Number:	6989166
Application Number:	10871001
Application Number:	10472438
Application Number:	10178736
Application Number:	09566381
Application Number:	09500802
Application Number:	09770773
Application Number:	10697428
Application Number:	09899922
Application Number:	10518632
Application Number:	10433308

CORRESPONDENCE DATA

Fax Number: (617)526-9899

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 617.526.9600

Email: oandrews@proskauer.com

Correspondent Name: Proskauer Rose LLP

Address Line 1: One International Place

Address Line 4: Boston, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	31680/018
-------------------------	-----------

NAME OF SUBMITTER:	Scott K. Witonsky
--------------------	-------------------

Total Attachments: 13

source=(12307304)_(1)_GNC - Termination and Release of Security Interest - Patents FINAL#page1.tif

source=(12307304)_(1)_GNC - Termination and Release of Security Interest - Patents FINAL#page2.tif

source=(12307304)_(1)_GNC - Termination and Release of Security Interest - Patents FINAL#page3.tif

source=(12307304)_(1)_GNC - Termination and Release of Security Interest - Patents FINAL#page4.tif

PATENT

REEL: 025905 FRAME: 0055

source=(12307304)_(1)_GNC - Termination and Release of Security Interest - Patents FINAL#page5.tif
source=(12307304)_(1)_GNC - Termination and Release of Security Interest - Patents FINAL#page6.tif
source=(12307304)_(1)_GNC - Termination and Release of Security Interest - Patents FINAL#page7.tif
source=(12307304)_(1)_GNC - Termination and Release of Security Interest - Patents FINAL#page8.tif
source=(12307304)_(1)_GNC - Termination and Release of Security Interest - Patents FINAL#page9.tif
source=(12307304)_(1)_GNC - Termination and Release of Security Interest - Patents FINAL#page10.tif
source=(12307304)_(1)_GNC - Termination and Release of Security Interest - Patents FINAL#page11.tif
source=(12307304)_(1)_GNC - Termination and Release of Security Interest - Patents FINAL#page12.tif
source=(12307304)_(1)_GNC - Termination and Release of Security Interest - Patents FINAL#page13.tif

**TERMINATION AND RELEASE OF SECURITY INTEREST
IN PATENT RIGHTS**

TERMINATION AND RELEASE, dated as of March 4, 2011, from JPMorgan Chase Bank, N.A., a national banking association, as administrative agent (the "Administrative Agent") for the Secured Parties (as defined in the Credit Agreement referred to below), to General Nutrition Investment Company, an Arizona corporation (the "Grantor"), and each of entities listed on Schedule 1 hereto (collectively, with Grantor, the "Grantors").

WITNESSETH:

WHEREAS, pursuant to that certain Credit Agreement, dated as of March 16, 2007 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Credit Agreement"), among GNC Corporation, a Delaware corporation, General Nutrition Centers, Inc., a Delaware corporation (the "Borrower"), the Lenders from time to time party thereto, J.P. Morgan Securities Inc. and Goldman Sachs Credit Partners L.P., as the Arrangers, Goldman Sachs Credit Partners L.P., as the Syndication Agent, the Administrative Agent, Merrill Lynch Capital Corporation and Lehman Commercial Paper Inc., as the Documentation Agents, the Secured Parties agreed to extend credit to Borrower subject to the terms and conditions set forth therein;

WHEREAS, in connection with the Credit Agreement, the Grantor entered into a Guarantee and Collateral Agreement, dated as of March 16, 2007, (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Guarantee and Collateral Agreement"), in favor of the Administrative Agent for the benefit of the Secured Parties;

WHEREAS, pursuant to the Guarantee and Collateral Agreement, a security interest (the "Security Interest") was granted by the Grantors to the Administrative Agent in certain Collateral, including the Patent Collateral (as hereinafter defined);

WHEREAS, pursuant to that certain Intellectual Property Security Agreement dated as of March 16, 2007 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Security Agreement"), made by the Grantors in favor of the Administrative Agent for the ratable benefit of the Secured Parties, Grantors, by reference to the Guarantee and Collateral Agreement, reaffirmed its intent to grant a Security Interest to the Administrative Agent specifically in the Patent Collateral;

WHEREAS, the Security Agreement was recorded in the United States Patent and Trademark Office on June 10, 2009 at Reel 022804 and Frame 0237; and

WHEREAS, the Administrative Agent now desires to terminate and release the entirety of its Security Interest in the Patent Collateral;

NOW, THEREFORE, for good and valuable consideration including the satisfaction of all outstanding Obligations and any other obligations, indebtedness and liabilities owing by the Grantors under the Loan Documents secured by the Patent Collateral pursuant to the Guarantee and Collateral Agreement, the receipt and adequacy of which are hereby acknowledged, and upon the terms set forth in this Termination and Release, the Administrative Agent hereby states as follows:

1. Definitions. The term "Patent Collateral," as used herein, shall mean all of any Grantor's right, title and interest of every kind and nature as of the date hereof in the Patents listed on Schedule 2 hereto. The term "Patents" shall mean: (i) all United States and foreign patents, patent applications and patentable inventions, and all certificates of invention or similar property rights, (ii) all inventions and improvements described and claimed therein, (iii) the right to sue or otherwise recover for any and all past, present and future infringements and misappropriations thereof, (iv) all income, royalties, damages and other payments now and hereafter due and/or payable with respect thereto, and (v) all reissues, divisions, reexaminations, continuations, continuations-in-part, substitutes, renewals, and extensions thereof, all improvements thereon and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto.

2. Release of Security Interest. The Administrative Agent hereby terminates, releases and discharges its Security Interest in the Patent Collateral, and any right, title or interest of the Administrative Agent in such Patent Collateral shall hereby cease, be of no further force or effect and become void.

3. Further Assurances. The Administrative Agent hereby agrees to duly execute, acknowledge, procure and deliver any further documents and to do such other acts as may be reasonably necessary to effect, evidence or reflect of public record the release of the Security Interest contemplated hereby.

IN WITNESS WHEREOF, the undersigned has executed this Termination and Release by its duly authorized officer as of the date first above written.

JPMorgan Chase Bank, N.A.

By: _____

Name: Barry K. Bergman

Title: Managing Director

[Signature Page to Patent Release]

SCHEDULE 1

GRANTORS:

GNC CORPORATION
GENERAL NUTRITION CENTERS, INC.
GENERAL NUTRITION INCORPORATED
GENERAL NUTRITION CORPORATION
NUTRA MANUFACTURING, INC.
GENERAL NUTRITION INTERNATIONAL, INC.
GENERAL NUTRITION SYSTEMS, INC.
GENERAL NUTRITION DISTRIBUTION COMPANY
GNC CANADA LIMITED
GNC (CANADA) HOLDING COMPANY
INFORMED NUTRITION, INC.
GENERAL NUTRITION GOVERNMENT SERVICES, INC.
GN INVESTMENT, INC.
GNC FRANCHISING, LLC
GNC US DELAWARE, INC.
GNC CARD SERVICES, INC.
GNC FUNDING, INC.
NUTRA SALES CORPORATION
GENERAL NUTRITION DISTRIBUTION, L.P.
GENERAL NUTRITION COMPANIES, INC.

SCHEDULE 2

See attached.

GNC PATENTS

Patent Title	Patent #	Issue Date	Country	Owner
Method and Apparatus for Preparation of Capsule with Improved Closing/Ejection Pins	6,546,702	April 15, 2003	US	Nutricia Manufacturing USA, Inc.
NADM/NADPM -Containing Compound	US Patent Application No. 10/535,330	Filed May 18, 2005	US	Nutropia Ernährungsmedizinische Forschungs GmbH

DALLAS 1752958v1

NUMICO PATENTS AND PATENT APPLICATIONS ASSIGNED & LICENSED TO GNC

GNC Product	Patent Title	Appln. No.	Date Filed	Publ. No.	Date Issued	Country	Status
CATEGORY A							
PN Cartilla	Composition for the Treatment of Osteoarthritis	US 09/662,123	9/14/2000	US 6,492,429	12/10/2002	United States	Patented - Active
		AU 20010072849D		AU 7284901		Australia	Withdrawn 8/5/2005
		EP 20010952054	2/7/2003	EP 1347766		Europe	
		PCT/NL01/00525	7/10/2001	WO02/004003			
Migra Plex	Composition for the Treatment of Migraine	US 09/613,573	7/11/2000	US 6,465,517	10/15/2002	United States	Patented -Active
		AU 20010072852D	1/21/2002	AU 7285201		Australia	Lapsed
		EP 20010952057	7/11/2000	EP 1299011		Europe	Withdrawn 6/10/2005
Heart Advance?	Cholesterol Lowering Supplement	US 09/726,308	12/1/2000	US 2002/0068095 6,933,291	8/23/2005	United States	
		CA 20012430315	5/29/2003	CA 2430315		Canada	
		EP 01998234.7	1/10/2003	EP 1337162		Europe	
		PCT/NL01/00866	11/29/2001	WO2002/043506		PCT	
		US 10/433,308	6/2/2003	US 2005/0100619		United States	
No Commercial Product (ASU & Celery Seed)	Composition and Method for the Treatment of Prevention of IL-1 Mediated Disorders	PCT/NL03/00250	4/3/2003	WO 03/082310		PCT	GNIC is Applicant
		US 09/581,475	6/14/2000	US 6,605,296	8/12/2003	United States	Registered Active
No Commercial Product (Red wine extract)	Natural Substances Based Agent	AT 19980000525D		AT 407821B		Austria	
CATEGORY B							
Assigned to GNC for Protected Business - Excl. License back to Numico for Non-Protected Business							
Body Answers	Dietetic Preparation and	US 09/880,937	6/15/2001	US 2003/0004215		United States	Abandoned

Category A - B = GNC's Expense to Maintain
Category D - F = Numico's Expense to Maintain

GNC Product	Patent Title	Appln. No.	Date Filed	Publ. No.	Date Issued	Country	Status
Complete with Phase 2	Method for Inhibiting Intestinal Carbohydrate Absorption	US 10/480,487	4/16/2004	2004/0171694		United States	7/14/2003
		PCT 2002NL00394	6/14/2002	WO 02/102362		PCT	Active
		US 09/812,839	3/21/2001	US 2002/0172732		United States	Abandoned 7/28/2003
		US 10/608,095	6/30/2003	US 2004/0005347		United States	Abandoned 3/6/2006
Women's Ultra Mega Vitapak	Composition Comprising Cocoa	AU 2002241397	10/3/2002			Australia	Lapsed
		CA 2441616	9/22/2003			Canada	
		EP 02707335.2	9/17/2003	EP 1370273		Europe	Withdrawn 1/14/2005
		PCT/NL02/00184	3/21/2002	WO/02/074321		PCT	
No Commercial Product	Reducing Appetite in Mammals by Administering Procyanidin and Hydroxycitric Acid	US 09/956,463	9/20/2001	6,638,542	10/28/2003	United States	Registered-Active
		PCT 2002NL00607	9/20/02	WO 03/024245		PCT	Active
		CA	3/18/2004	2460824		Canada	
		GB	3/22/04	GB0406384.8		Great Britain	
Total Lean	Method for the Treatment and Prevention of Overweight in Mammals	US 10/384,750	3/11/2003	US 2003/0175368		United States	Active Allowed 12/28/2006
		PCT/NL03/00179	3/11/2003	WO 03/075941		PCT	Active; GNIC is Applicant
		CA 2478663	9/9/2004			Canada	
Total Lean Control	Method for the Reduction of Mammalian Appetite	PCT/NL03/00198	3/18/2003			PCT	Active; GNIC is Applicant
		US 10/535,258	1/18/2006	US 2006/0135444		US	
TBD	Method for the Prevention or Treatment of Overweight in Mammals	US 10/323,826	12/20/2002	US 2004/0247699		United States	Abandoned 10/13/2005

Category A - B = GNC's Expense to Maintain
Category D - F = Numico's Expense to Maintain

GNC Product	Patent Title	Appln. No.	Date Filed	Publ. No.	Date Issued	Country	Status
TBD	Stimulation of In Vivo Production of Proteins	US 10/325,711	12/20/2002	US 2004/0122097		United States	
PN Liver Formula	Method of Increasing the Presence of Glutathione in Cells	US 09/639,469	8/16/2000	US 6,495,170	12/17/2002	United States	Registered Active
		DE 20011051148		DE 10151148		Germany	Active
		PCT2001EP10671	9/14/2001	WO 03/024487		PCT	Active
		US 10/284,158	10/31/2002	US 2003/0054048		United States	Abandoned 9/5/2006
		AU 2002212244	1/16/2004			Australia	Lapsed
		CA 2459547	3/12/2004			Canada	
		CN 01823625.1	3/12/2004			China	
		JP 2003/528581	3/9/2004			Japan	
TBD	Compositions Suitable for the Treatment of Damage Caused by Ischemia/Reperfusion or Oxidative Stress	PCT/NL01/00233	3/22/2001	WO 01/70248		PCT	
		AU 20010042876D	10/3/2001	AU 4287601		Australia	Lapsed
		US 10/239,429	1/15/2003	2004/0076692		United States	Abandoned 3/5/2007
		EP 20000201051		EP 1136073		Europe	Withdrawn 11/29/2002
		EP 20010915929	9/20/2002	EP 1267901	11/8/2005	Europe	
		JP 200110568445T		JP 2003527434		Japan	
PN Resistance Plan	Chlorogenic Acid and an Analog Thereof for Immune System Stimulation	US 09/734,389	8/15/2002	US 6,632,459	10/13/2003	United States	Registered Active
		10/612,242	7/2/2003	US 2004/0097584		United States	Pending
		AU 20020025512D	12/10/2001	AU 2551202		Australia	Lapsed
Diabetes Plan?	Method for the Treatment of Obesity, Overweight and Fluctuations in Blood Insuline and/or Glucose Levels	US 10/015,582	12/17/2001	US 2003/0113310		United States	Abandoned 2/18/2005
		PCT/NL02/00836	12/17/2002	WO 03/051391		PCT	

GNC Product	Patent Title	Appln. No.	Date Filed	Publ. No.	Date Issued	Country	Status
CATEGORY D	Nonexclusive license to GNC for Protected Business						
PN Prostate	Anti-Proliferative Composition	PCT/NL02/00764	11/25/2002	WO 03/043658		PCT	Non-exclusive. Licensed to GNC, and may be term. for Prot. Bus.
		US 10/496,411	5/21/2004	US 2004/2059815		United States	
		JP 2003545336	5/21/2004			Japan	
		CA 2468180	5/21/2004			Canada	
		CN 02827989.X	7/23/2004			China	
		EP 20010204495		EP 1314438		Europe	Withdrawn 7/16/04
CATEGORY E	Nonexclusive license to GNC for Protected Business						
Total Lean MRP National Brand Fiber Sense	Nutritional Composition Containing Fibres	US 08/691,023	8/5/1996	US 5,792,754	8/11/1998	United States	
		CAN 09/102,085					abandoned
		AU 19960060871		AU 702989		Australia	
		EP 19950202142	8/4/1995	EP 0756828	7/20/1998	Europe	Granted, Amended 5/20/2002 following appeal
		DE 19956006095		DE 69506095T		Germany	
		ES 19950202142T		ES 2123903T		Spain	
Mega Creatine Creatine Clear	Composition Containing Creatine and Phosphorus	US 09/769,245	1/26/2001	US 2002/150627		United States	Abandoned 4/12/2005
AU 2002228484		1/28/2002			Australia	Lapsed	
CA 20022434104		7/22/2003	CA 2434104		Canada		
EP 20020710564		4/25/2003	EP 1353568		Europe	Withdrawn 2/3/2006	
PCT/NL02/00062		1/28/2002	WO/02/058488		PCT		
CATEGORY F	Nonexclusive license to GNC for protected business, but Numico may assign to GNC if not willing to prosecute						
TBD	Soft Drink Replacer	US 10,279,968	10/25/2002	US 2003/0134027	1/24/2006	United States	
		PCT/NL02/00857	12/20/2002	WO 03/053169		PCT	
		US 6,989,166	1/24/2006			United States	
		US 10/871,001	6/21/2004	US 2004 0228903		United States	

Category A - B = GNC's Expense to Maintain
Category D - F = Numico's Expense to Maintain

GNC Product	Patent Title	Appln. No.	Date Filed	Publ. No.	Date Issued	Country	Status
		CA 2470791	6/17/2004			Canada	
		CN 02828217.5	8/19/2004			China	
		JP 2003553935	6/18/2004			Japan	
No Commercial Product (New bone concept)	Preparation for the Prevention and/or Treatment of Altered Bone Metabolism	PCT/NL02/00186	3/22/2002	WO 02/076241		PCT	
		US 10/472438	3/29/2004	US 2004 0152640		United States	
CATEGORY G	Exclusive worldwide license to GNC for Protected Business						
Distance, Energel Fuel Powder	Nutritional Preparation Comprising Ribose and Medical Use Thereof	US 10/178,736	6/25/2002	US 6,548,483	4/15/2002	United States	
		US 09/566,381	5/8/2000	US 6,420,342	7/16/2002	United States	
		AU 20010056856D	5/8/2001	AU 5685601		Australia	Lapsed
		CN 20010809177T		CN 1429113T		China	
		EP 20010930315	10/28/2002	EP 1282426		Europe	
Mega MRP	Pharmaceutical Composition for Muscular Anabolism	US 09/500,802	2/10/2000	US 6,521,591	2/18/2003	United States	
		AU 20010037809D	8/20/2001	AU 3780901	7/22/2005	Australia	
		CA 20012398990	8/8/2002	CA 2398990		Canada	
		EP 20010910231	8/5/2002	EP 1253830		Europe	
		PCT/NL01/00112	2/12/2001	WO/01/058284		PCT	
During Hydration Powder (Endurance)	Rehydration Composition	US 09/770,773	1/26/2001	US 2002/0176881		United States	Abandoned 10/18/2004
		US 10/697,428	10/30/2003	US 2004/0087518		United States	
		AU 2002230270	1/28/2002	30270/02	8/17/2006	Australia	
		PCT/NL02/00063	1/28/2002	WO/02/058792		PCT	
		CA 20022436764	7/25/2003	CA 2436764		Canada	
		EP 20020711526	8/4/2003	EP 1353726		Europe	
Memorail	Method and Preparation for the Preventing	US 09/899,922	7/9/2001	US 2002/0040058		United States	Issued fee paid 3/9/2007

Category A - B = GNC's Expense to Maintain
Category D - F = Numico's Expense to Maintain

GNC Product	Patent Title	Appln. No.	Date Filed	Publ. No.	Date Issued	Country	Status
	and/or Treating Vascular Disorders and Secondary Disorders Associated Therewith	AU 20010025114D	5/8/2001	AU 5511401		Australia	Lapsed
		CA 20012408032	11/6/2002	CA 2408032		Canada	
		CN 20010812461T	1/7/2003	CN 1440240T		China	
		EP 20010205113		EP 1275399		Europe	
		EP 20010928256	12/9/2002	EP 1282365		Europe	
		PCT/NL01/00347	5/8/2001	WO/2001/1084961		PCR	
Creatine Burst Pre Creatine	Nutritional or Pharmaceutical Compositions for Increasing the Creatine Response of Organisms	PCT/NL03/00448	6/19/2003	WO/2004/000297		PCT	
		US 10/518,632	7/11/2005	2005/0287294		United States	
Pro Protein?	Composition for Treating and Preventing Catabolism or Stimulating Anabolism in a Mammal Undergoing Metabolic Stress	PCT/NL03/00449	6/19/2003	WO/04/000042		PCT	
		CN 03819314.0	2/16/2005			China	
		JP 2004/530928	12/17/2004			Japan	

GNC PATENTS

Patent Title	Patent #	Issue Date	Country	Owner
Method and Apparatus for Preparation of Capsule with Improved Closing/Ejection Pins	6,546,702	April 15, 2003	US	Nutricia Manufacturing USA, Inc.
NADM/NADPM - Containing Compound	US Patent Application No. 10,535,330	Filed May 18, 2005	US	Nutropia Ernährungsmedizinische Forschungs GmbH

HOUSTON 921999v2

Category A - B = GNC's Expense to Maintain
Category D - F = Numico's Expense to Maintain